olezarsen
olezarsenoligonucleotideApoCIII antisense oligonucleotide
Familial Chylomicronemia
Filed
1 program·1 trial·View drug →
DashboardSell6,265$40.34−$252.7KOption ex.8,247$34.34$283.2KBuy577,146$42.08+$24.3MOption ex.13,052$45.88$598.8KSell49,160$40.28−$2.0M NephrologyResearch Grant$739.9K6NephrologyResearch Grant$584.3K5NephrologyResearch Grant$575.7K4NephrologyCo-Investigator$565.4K5NephrologyResearch Grant$549.8K6CardiologyCo-Investigator$423.8K5CardiologyCo-Investigator$353.9K7NephrologyEquity / Ownership$163.8K3NephrologyResearch Grant$125.5K4NephrologyCo-Investigator$116.0K2
IONSNASDAQ
Ionis
Ionis Pharmaceuticals, Inc. · Carlsbad, CA · founded 1989
Ionis Pharmaceuticals, based in Carlsbad, California, develops antisense oligonucleotide (ASO) drugs — short synthetic strands of DNA-like molecules that bind to a target RNA and prevent the cell from producing a disease-driving protein. The portfolio includes SPINRAZA for SMA (partnered with Biogen), WAYLIVRA for familial chylomicronemia, and TRYNGOLZA for severe hypertriglyceridemia, plus late-stage programs across cardiovascular, neurological, and rare diseases.
- Lead asset
- olezarsen · Filed · Familial Chylomicronemia
- oligonucleotide · ApoCIII antisense oligonucleotide
- Pipeline
- 1 drug · 1 program
- 1 Cardio-Renal
- Modalities
- oligonucleotide×1
FocusRare DiseaseCardio-RenalNeurology
$41.00+4.89%1Y
IONS · daily close · illustrative · 0 catalysts marked
1Y high$48.721Y low$38.46range$10.26(27%)past catalysts
Peers in this space
Pipeline & catalysts
Pipeline & catalysts
Pipeline by phase1programs
- Preclin0
- Ph10
- Ph20
- Ph30
- Filed1
- Approved0
Past catalyst impact
DateKindEventOutcome+1W+1M+6M
Mar 1, 2025PDUFAolezarsen — PDUFA — ApprovedPositive+40.1%+24.6%+43.1%
Jan 30, 2025Readoutolezarsen — Phase 3 Topline — Mixed ResultNegative-14.0%-43.9%-22.8%
Dec 31, 2024PDUFAolezarsen — PDUFA — CRL IssuedNegative-26.7%-26.7%-20.3%
Nov 7, 2023Interimolezarsen — Phase 3 Interim — Stopped for EfficacyPositive+14.8%+20.1%+10.1%
% change vs ticker close on the announcement date · backtest illustrative
Smart money
Insider activity
Insider activity · last 90 days
Form 4 trail · 5 transactions · 5 insiders
Net flow
+$22.1M
Buys
$24.3M
1 txns
Sells
$2.2M
2 txns
Largest
+$24.3M
10% Owner buy
Net flow per quarter · last 8Q
11 txns · sum +$19.18M
24Q325Q125Q326Q126Q2
buys · $26.13Msells · $6.94M
Insider · roleActionSharesPriceValueDate
S. Iyer
SVP
Apr 19, 2026
L. Reyes
CEO
Mar 27, 2026
M. Hassan
10% Owner
Feb 28, 2026
E. Goldstein
CMO
Feb 27, 2026
R. O'Connor
CEO
Jan 26, 2026
Congressional trading
Congressional trading · STOCK Act · last 365d
6 trades · 6 members
Est. net flow
+$6.20M
midpoint · brackets only
Buys
4
Sells
2
Party mix
4 D2 R
Member · chamberActionBracket~ midpointOwnerDate · disclosure
R
Buy$1.00M–$5.00M~$3.00MselfRep. Q. Yates
House · AL
Feb 14, 2026
filed +28d
D
Buy$15K–$50K~$33KselfSen. E. Mendoza
Senate · AZ
Feb 9, 2026
filed +42d
D
Buy$250K–$500K~$375KspouseSen. C. Walsh
Senate · NY
Jan 12, 2026
filed +38d
D
Sell$15K–$50K~$33KdependentRep. K. Linville
House · WA
Nov 19, 2025
filed +1d
D
Sell$100K–$250K~$175KspouseSen. A. Reyes
Senate · CA
Sep 28, 2025
filed +22d
R
Buy$1.00M–$5.00M~$3.00MjointRep. J. Calhoun
House · GA
May 17, 2025
filed +38d
Source: Senate eFD & House Clerk PTR feeds · members must disclose within 45 days · midpoints reflect bracket midpoint, not actual transaction value
Top ETF holders
ETF holders · NAV disclosures
4 ETFs hold the position
Held by ETFs
$61.0M
aggregate position
Of market cap
1.05%
aggregate ETF share
Top holder
IBB0.31%
iShares Biotechnology ETF
TickerETF · familyThemeNAV% of NAVPosition
IBBBroad biotech$8.40B0.31%$26.0M
iShares Biotechnology ETF
iShares
XBIBroad biotech$7.90B0.32%$25.3M
SPDR S&P Biotech ETF
SPDR
IDNAGenomics$200.0M4.53%$9.1M
iShares Genomics Immunology Healthcare
iShares
PBEBroad biotech$175.0M0.34%$595K
Invesco Dynamic Biotechnology
Invesco
Source: ETF NAV disclosures + quarterly 13F filings · narrow-theme ETFs disclose holdings daily; broad ETFs quarterly · % of NAV is the position weight inside the fund
KOL network
KOL network · CMS OpenPayments
16 physicians paid · 68 disclosed records
Total 2025+2024
$4.48M
YoY
-16%
Research Grant$2.06MCo-Investigator$1.75MEquity / Ownership$276.5KConsulting$261.6KSpeaking$92.1KTravel & Lodging$42.6KFood & Beverage$2.3K
Physician · affiliationSpecialtyTop categoryTotalRecords
Dr. Charles Mendoza
NYU Langone
Dr. Rebecca Romano
MD Anderson
Dr. Olivia Kowalski
Yale Medical
Dr. Robert Reyes
MD Anderson
Dr. Anita Lindberg
Cedars-Sinai
Dr. Olivia Reyes
Cleveland Clinic
Dr. Ahmed Davies
NYU Langone
Dr. Henry Park
NYU Langone
Dr. Sarah Tanaka
Memorial Sloan Kettering
Dr. Yuki Kowalski
Cleveland Clinic
Source: CMS OpenPayments · quarterly drops · physicians identified by NPI · aggregated across all programs
Government & IP
Federal lobbying
Federal lobbying · LDA · last 8 quarters
$983K disclosed · 3 firms engaged
YoY change
+23%
last 4Q vs prior 4Q
24Q3Q425Q1Q2Q3Q426Q1Q2
Top lobbying firms · last 8Q
BGR Group$491K
6 quarters active
K&L Gates$312K
5 quarters active
Brownstein Hyatt Farber Schreck$180K
3 quarters active
Top issues lobbied
- FDA user fee reauthorization (PDUFA / BsUFA)$595K
- NIH appropriations · NCI funding$104K
- Prescription Drug User Fee programs$104K
- Drug Supply Chain Security Act$90K
- BIOSIM Act / Biosimilars$90K
Source: Senate LDA database (lda.senate.gov) · quarterly registrant filings · spend is the company-wide total disclosed
Government contracts
Federal contracts · USAspending.gov
2 awards · 2 agencies
Total awarded
$19.4M
across all programs
Active
$19.4M
option periods incl.
Top agency
NIH / NIAID$17.4M
largest active: Antiviral Drug Discovery Cooperative
AgencyTitle · type · award IDStatusValueAwarded → ends
VAactive$2.0MApr 2026→ Sep 2027
Veterans Health Administration — Specialty Drug Supply
Contract · VA-89416725
NIH / NIAIDactive$17.4MAug 2023→ Aug 2026
Antiviral Drug Discovery Cooperative
Cooperative Agreement · NIH-66059979
Source: USAspending.gov · SAM.gov · every federal contract / grant / cooperative agreement is public · values are obligated awards (may include option periods)
U.S. Patents
U.S. Patents · USPTO
1 granted · 5 pending
Total in portfolio
6
Granted in last 12mo
1
Expiring < 2yr
0
Nearest expiry
Apr 2046
Patent #Title · inventor · drugTypeStatus · filedExpiry
10,199,458Process
Purification methods for olezarsen
A. Voss + 1 · olezarsen
grantedfiled Apr 2026
exp. Apr 2046
20.0y left
US 2025/3909535 A1Composition of Matter
Small molecule modulators of olezarsen
A. Chen · olezarsen
pendingfiled Apr 2025
in prosecution
US 2025/4969855 A1Method of Use
Pediatric methods of use for olezarsen
D. Reyes + 2 · olezarsen
pendingfiled Apr 2025
in prosecution
US 2024/2012650 A1Composition of Matter
Therapeutic peptide compositions for olezarsen
D. Park + 2 · olezarsen
pendingfiled Apr 2024
in prosecution
US 2022/2013985 A1Method of Use
Methods of stratifying patients for treatment with olezarsen
F. Goldstein · olezarsen
pendingfiled Apr 2022
in prosecution
US 2021/3383598 A1Composition of Matter
Bispecific antibody compositions targeting olezarsen
B. Andersson + 3 · olezarsen
pendingfiled Apr 2021
in prosecution
Source: USPTO PEDS & Patent Public Search · composition-of-matter is the headline asset · expiration = 20 years from filing
News
News
News · last 90 days
10 items from 5 categories
regulatory3clinical3corporate2analyst1partnership1
just now
EMA validates IONS's Marketing Authorization Application for olezarsen
PR Newswire·regulatory
5d ago
IONS adds independent director to Board
Business Wire·corporate
7d ago
FDA accepts IONS's NDA for olezarsen; PDUFA date set
FierceBiotech·regulatory
20d ago
Sell-side raises price target on IONS after pipeline review
Reuters·analyst
23d ago
IONS reports topline results from Phase 2 trial of olezarsen
Endpoints News$·clinical
1mo ago
IONS reports topline results from Phase 2 trial of olezarsen
Endpoints News$·clinical
1mo ago
IONS appoints new Chief Medical Officer
PR Newswire·corporate
1mo ago
EMA validates IONS's Marketing Authorization Application for olezarsen
FierceBiotech·regulatory
2mo ago
IONS expands co-development partnership for next-gen pipeline
Business Wire·partnership
3mo ago
IONS doses first patient in Phase 3 olezarsen study
Endpoints News$·clinical
Sources: PR wires + biotech-trade publications + company IR · paywalled outlets ($) link to publisher · we never paraphrase the headline
Financials
Financials
Trading
Previous close
$41.00
Open
$41.33
Day Δ
-0.33
-0.80%
Day range
$40.73 – $41.60
52W range
$38.46 – $48.72
Avg daily volume
1.08M
Valuation & ownership
Enterprise value
$4.7B
Shares out
141.46M
Float
130.14M
Insider %
1.63%
Institutional %
71.63%
Beta
1.13
vs SPY · 52w
Balance sheet & burn
Cash + invest
$2.0B
Total debt
$365M
Debt / equity
3.63
Cash burn / Q
$140M
R&D spend TTM
$532M
27% of cash
ATM available
None
no active facility
Earnings
EPS latest
$-0.18
EPS Δ vs prior
+0.03
EPS estimate
$-0.15
next quarter
EPS prior
$-0.21
Next earnings
May 16, 2026
Rev guidance
$104M